All Posts By

Smartkarma Daily Briefs

Daily Brief China: JD.com Inc (ADR), Goldman Sachs Group and more

By | China, Daily Briefs

In today’s briefing:

  • [JD.com, Inc (JD US, BUY, TP US$52) TP Change]: C4Q24 Preview: Still the Safe Choice into 2025
  • Asia Real Estate Tracker (24-Jan-2025): Goldman Sachs expands into Japan with data centre JV.


[JD.com, Inc (JD US, BUY, TP US$52) TP Change]: C4Q24 Preview: Still the Safe Choice into 2025

By Ying Pan

  • We expect JD.com C4Q24 revenue/non-GAAP NI to be RMB337bn/9.7bn, 1.6%/6.5% above consensus, benefiting from trade-in subsidies and logistics;
  • With 2025 having four quarters of trade-in subsidy vs. 2024’s one quarter and smartphone’s participation, JD.com is on solid growth footing in our universe. 
  • We raised JD.com’s TP from US$50 to US$ 52 TP and maintain BUY rating.

Asia Real Estate Tracker (24-Jan-2025): Goldman Sachs expands into Japan with data centre JV.

By Asia Real Estate Tracker

  • Goldman Sachs’ GCI enters partnership with Asia Pacific Land in Japan for data center venture, expanding its reach in Asia.
  • CPPIB and MGRV collaborate on $350M venture in Korean rental housing, aiming to capture opportunities in the real estate market.
  • S&P forecasts rebound in China’s property market, driven by increase in secondary sales, indicating positive growth.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Tsuruha Holdings, Resona Holdings, SGX Rubber Future TSR20, TSE Tokyo Price Index TOPIX, Astellas Pharma and more

By | Daily Briefs, Japan

In today’s briefing:

  • Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table
  • Japanese Big Cap Banks – Revisiting Interest Rate Sensitivities
  • Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber
  • ETF Sale Won’t Be Concluded Soon, but as Long as BOJ Keeps Holding Them, the Problems Will Persist
  • Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt


Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table

By Travis Lundy

  • In late December, a Jiji article said Tsuruha & Welcia would look to integrate by end-2025, now that they no longer need SEC approval. Odd language, but we’ll take it.
  • That means we look to what might happen between here and there. The companies will hire Legal and Financial Advisors, wait until both report FY, then start negotiating.
  • What has been the long-term trend and the trend of the last two years is different. It’s worthwhile looking at valuations and expectations to decide how to trade. It’s good.

Japanese Big Cap Banks – Revisiting Interest Rate Sensitivities

By Victor Galliano

  • BoJ raised rates to 0.5% at its January policy meeting and BoJ Governor Kazuo Ueda hinted at more rate hikes; BoJ’s new Outlook Report forecasts higher core inflation in 2025
  • We reiterate our core recommendations Resona and Mizuho for their leverage to higher interest rates, their low LDRs, their high levels of cash at the BoJ and their modest valuation
  • We also keep our buys on Concordia and Shizuoka, for their leverage to higher interest rates and LDRs below 90%, along with their attractive valuations highlighted by low PEGs

Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber

By Vinod Nedumudy

  • Transaction valued at around US$701 million in cash proceeds
  • Goodyear to hold ground in Europe until the end of 2025
  • Goodyear joins Dutch research body TNO for crash mitigation

ETF Sale Won’t Be Concluded Soon, but as Long as BOJ Keeps Holding Them, the Problems Will Persist

By Aki Matsumoto

  • Since dividend income and unrealized gains on ETFs have significant impact on BOJ’s finances, the sales of ETF will be discussed, considering BOJ’s overall balance sheet and income/expenses as well.
  • There’re unexamined issues, whether the central bank’s purchase of stocks was really good thing, whether it distorted the secondary market, and whether management reforms were delayed by underpinning the stocks.
  • BOJ can move on to the issue of ETF disposition when the impact of policy rate hikes is recognized and the market stabilizes, but until then the problems will persist.

Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt

By Tina Banerjee

  • Astellas Pharma (4503 JP) revised FY25 revenue guidance upward to ¥1900B on robust Xtandi performance and favourable forex movement. Core profits and margins will also see upward revisions and expansions.
  • The company will record an impairment charge of ¥176B for intangible assets this fiscal. As a result, FY25 operating profit on reported basis will come down to ¥11B from ¥80B.
  • Recently, Astellas has received approval for Vyloy and label expansion approval for Padcev in China. Label expansion application for Izervay in the U.S. has been accepted by the FDA.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: ZTO Express Cayman , Cameco Corp, Japfa Comfeed Indonesia, Tsuruha Holdings, IAMGOLD , MongoDB , T’Way Holdings, Malaysia Airports Holdings, Samsung Electronics, Sichuan Biokin Pharmaceutical Co Ltd and more

By | Daily Briefs, Most Read

In today’s briefing:

  • ZTO Express (2057 HK): On Track for Double (Maybe Triple) Index Inclusion
  • Solactive Global Uranium & Nuclear Components Index Rebalance Preview: Potential Changes Next Week
  • IDX30/​​LQ45/IDX80 Index Rebalance: Big Impact in Some Stocks with 4 Days to Implementation
  • Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table
  • [Quiddity Index Jan25] MV Junior Gold Miners Index Mar 25 Rebal: Multiple Adds, 4.4% 1-Way Turnover
  • Nasdaq100 Dec2025 Forecast (Part 1): MDB & BIIB in Trouble; UAL & ALNY First Replacements
  • StubWorld: T’Way Air (091810 KS) Takes Off As Key Shareholder Seeks Board Spill
  • Malaysia Airports (MAHB MK): Lower Acceptance Condition Assures Completion
  • Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion
  • Sichuan Biokin (百利天恒) H-Listing: Impressive Clinical Results so Far


ZTO Express (2057 HK): On Track for Double (Maybe Triple) Index Inclusion

By Brian Freitas

  • With improved liquidity, ZTO Express Cayman (2057 HK) could be added to the HSCEI INDEX early March and then to a global index a couple of weeks later.
  • ZTO Express Cayman (2057 HK) is a lower probability inclusion to the Hang Seng Index (HSI INDEX) given the index committee discretion. Inclusion would further increase the impact.
  • The stock has had a big drawdown recently and the potential index inclusion and passive demand provide a low-risk entry point into the stock, especially hedged with its peers.

Solactive Global Uranium & Nuclear Components Index Rebalance Preview: Potential Changes Next Week

By Brian Freitas

  • Based on prices and turnover from 22 January, there could be one deletion from the index in January. Plus there will be capping and float changes.
  • There are four stocks that meet the inclusion criteria, but all are non-pure play companies, and the index is already at the limit of 15 non-pure play companies.
  • Estimated one-way turnover is 6.8% resulting in a round-trip trade of US$506m. There are many stocks with multiple days of ADV to trade.

IDX30/​​LQ45/IDX80 Index Rebalance: Big Impact in Some Stocks with 4 Days to Implementation

By Brian Freitas


Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table

By Travis Lundy

  • In late December, a Jiji article said Tsuruha & Welcia would look to integrate by end-2025, now that they no longer need SEC approval. Odd language, but we’ll take it.
  • That means we look to what might happen between here and there. The companies will hire Legal and Financial Advisors, wait until both report FY, then start negotiating.
  • What has been the long-term trend and the trend of the last two years is different. It’s worthwhile looking at valuations and expectations to decide how to trade. It’s good.

[Quiddity Index Jan25] MV Junior Gold Miners Index Mar 25 Rebal: Multiple Adds, 4.4% 1-Way Turnover

By Travis Lundy

  • The MV Junior Gold Miners Index represents the performance of small-cap gold and silver mining companies listed around the world.
  • This index is reviewed semi-annually in March and September. During these reviews, names can be added or deleted from the index.
  • Below we take a look at the latest lists of potential ADDs and DELs for the Index Rebal Event in March 2025. 

Nasdaq100 Dec2025 Forecast (Part 1): MDB & BIIB in Trouble; UAL & ALNY First Replacements

By Dimitris Ioannidis


StubWorld: T’Way Air (091810 KS) Takes Off As Key Shareholder Seeks Board Spill

By David Blennerhassett

  • A double dose of stubs this week! T’Way Air (091810 KS)‘s second-largest shareholder is seeking to spill the board. T’way Air and T’Way Holdings (004870 KS) are up big time.
  • Preceding my comments on the T’way Group are the current setup/unwind tables for Asia-Pacific Holdcos.
  • These relationships trade with a minimum liquidity of US$1mn, and a % market capitalisation >20%.

Malaysia Airports (MAHB MK): Lower Acceptance Condition Assures Completion

By David Blennerhassett

  • On the 17th January, Malaysia Airports Holdings (MAHB MK)‘s Offer was extended to the 24th January. Shares held by the Consortium plus tendering was then 86.18%. This looked done.
  • The closing date of the Offer could have been pushed out to 4th Feb. However the consortium has now opted to lower the acceptance threshold to 85% from 90%. 
  • Because of the revision, shareholders can withdraw shares tendered before the 28th January. But why would they? This is now very much done. And trading accordingly. 

Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion

By Sanghyun Park

  • Samsung Life needs FSC approval for a 10-year holding plan on its Samsung Electronics stake. Without it, the whole plan could fall apart, so it’s all about regulatory green lights.
  • If FSC approves Samsung Life’s long-term holding, they can’t sell those shares for at least 5 years—no exit strategy for the next half-decade due to regulatory rules.
  • Samsung Life will convert part of its stake into long-term holdings, signaling how future buybacks and special dividends will balance in Samsung Electronics’ next shareholder return program.

Sichuan Biokin (百利天恒) H-Listing: Impressive Clinical Results so Far

By Ke Yan, CFA, FRM

  • Sichuan Biokin is looking at a A-H listing and is looking to raise up to USD 500 million. 
  • In this note we look at the company’s fundamentals briefly including its heavyweight product BL-B01D1. We also examine its deal with BMS.
  • The stock has performed well on Shanghai STAR board since its A share listing. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Samsung Electronics, OpenAI, AU Optronics, Bharti Airtel, Blend Labs and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion
  • Stargate. It’s Not All About You Microsoft. Or You Either Elon
  • Tech Supply Chain Tracker (25-Jan-2025): HTC and VIA’s future?
  • Lucror Analytics – Morning Views Asia
  • Blend Labs Inc (BLND) – Friday, Oct 25, 2024


Converting Samsung Life’s Samsung Electronics Stake to Long-Term Holdings: Clearing up the Confusion

By Sanghyun Park

  • Samsung Life needs FSC approval for a 10-year holding plan on its Samsung Electronics stake. Without it, the whole plan could fall apart, so it’s all about regulatory green lights.
  • If FSC approves Samsung Life’s long-term holding, they can’t sell those shares for at least 5 years—no exit strategy for the next half-decade due to regulatory rules.
  • Samsung Life will convert part of its stake into long-term holdings, signaling how future buybacks and special dividends will balance in Samsung Electronics’ next shareholder return program.

Stargate. It’s Not All About You Microsoft. Or You Either Elon

By William Keating

  • President Donald Trump announced the Stargate Project, a new company which intends to invest $500 billion over four years building new AI infrastructure for OpenAI in the United States.
  • Elon Musk is miffed, Microsoft says they “approved” the project and have a new Right of First Refusal agreement in place with OpenAI. 
  • Stargate is exclusively for OpenAI and the press release states that its mission is to provide a strategic capability to protect the national security of America and its allies.

Tech Supply Chain Tracker (25-Jan-2025): HTC and VIA’s future?

By Tech Supply Chain Tracker

  • HTC and VIA are focusing on niche markets and expanding technological capabilities to stay relevant, while Japanese toolmakers turn to AI amid China market uncertainty.
  • Nvidia CEO highlights strategic partnership with China’s robotics unicorns, as Acer expands into lifestyle products with Acerpure line.
  • Singapore and Malaysia remain optimistic despite US AI chip restrictions, while India’s local EMS and semiconductor industries show growth in the technology sector.

Lucror Analytics – Morning Views Asia

By Trung Nguyen

  • In today’s Morning Views publication we comment on developments of the following high yield issuers: Bharti Airtel, SK Hynix, Adani Green Energy, Wynn Macau, New World Development
  • In the US, initial jobless claims for the week ended January 18th rose slightly to 223 k (220 k e / 217 k p). Meanwhile, continuing claims climbed to a three-year high of 1.90 mn (1.87 mn e / 1.85 mn p).
  • Treasuries ended mixed yesterday. The yield on the 2Y UST declined 1 bp to 4.29%, while the yield on the 10Y UST grew 3 bps to 4.64%.

Blend Labs Inc (BLND) – Friday, Oct 25, 2024

By Value Investors Club

  • BLND’s stock price has decreased, resembling CVNA’s past struggles
  • BLND has been restructuring its cost base and balance sheet to prepare for future growth
  • The company, led by a young CEO, is poised for potential recovery and positive earnings revisions, drawing parallels to CVNA’s path to success

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Dr. Reddy’s Laboratories, Beta Bionic, Akebia Therapeutics, Astellas Pharma and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Dr. Reddy’s Laboratories (DRRD IN): Q3FY25 Result- Subdued US Business Dents Margin; Somber Outlook
  • Beta Bionic, Inc. (BBNX): IPO Is An “Execution Story” And in Growth Mode
  • Akebia Therapeutics Inc (AKBA) – Friday, Oct 25, 2024
  • Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt


Dr. Reddy’s Laboratories (DRRD IN): Q3FY25 Result- Subdued US Business Dents Margin; Somber Outlook

By Tina Banerjee

  • Dr. Reddy’s Laboratories (DRRD IN) reported Q3FY25 US business revenue of INR33.8B, up 1% YoY, mainly dragged by lower contribution from Lenalidomide. Q3FY25 EBITDA margin deteriorated to 27.5% (Q3FY24: 29.3%).
  • Limited growth catalysts remain major overhang. No near-term key launches lined-up to fill the void created by Lenalidomide. Moreover, paltry new launches in the U.S. entail limited revenue visibility.
  • Lack of near-term catalyst and bleak growth outlook justify cheaper valuation of Dr. Reddy’s. We do not consider Dr. Reddy’s as value buying opportunity and remain bearish on the name.

Beta Bionic, Inc. (BBNX): IPO Is An “Execution Story” And in Growth Mode

By IPO Boutique

  • The company has jumped from just eight sales territories in Q2 2023 to 43 sales to end 2024 with more than 15,000 units installed.
  • An existing shareholder is on the cover of the prospectus with a concurrent private placement
  • Medical Device IPOs have a strong history of success as many are poised for growth

Akebia Therapeutics Inc (AKBA) – Friday, Oct 25, 2024

By Value Investors Club

  • Akebia Therapeutics aims to challenge the standard of care for anemia management in chronic kidney disease in the USA
  • Despite setbacks with FDA rejection of new drug Vafseo, company holds growth potential
  • Aims to have over 75,000 patients prescribed to Vafseo by end of 2026, leading to significant sales growth and operating profit; stock seen as undervalued with potential to reach price target of $5.00+

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Astellas Pharma (4503 JP): Xtandi & Forex Lead To Guidance Revision, Impairment Losses One Off Burnt

By Tina Banerjee

  • Astellas Pharma (4503 JP) revised FY25 revenue guidance upward to ¥1900B on robust Xtandi performance and favourable forex movement. Core profits and margins will also see upward revisions and expansions.
  • The company will record an impairment charge of ¥176B for intangible assets this fiscal. As a result, FY25 operating profit on reported basis will come down to ¥11B from ¥80B.
  • Recently, Astellas has received approval for Vyloy and label expansion approval for Padcev in China. Label expansion application for Izervay in the U.S. has been accepted by the FDA.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Seoul Guarantee Insurance, Samsung Life Insurance, Mediobanca SpA, Resona Holdings, Goldman Sachs Group, Geo Group and more

By | Daily Briefs, Financials

In today’s briefing:

  • Seoul Guarantee IPO: Price Cut, Dividend Focus, But Overhang and Weak Earnings May Hurt
  • Samsung Life Insurance: Implications of Classifying Samsung Electronics as a Long-Term Holding
  • Seoul Guarantee Insurance Corp IPO Preview (Significantly Lower IPO Price Range)
  • Monte Dei Paschi Di Siena’s €13.3 Billion Bid for Mediobanca: First Take
  • Japanese Big Cap Banks – Revisiting Interest Rate Sensitivities
  • Asia Real Estate Tracker (24-Jan-2025): Goldman Sachs expands into Japan with data centre JV.
  • Geo Group Inc (GEO) – Friday, Oct 25, 2024


Seoul Guarantee IPO: Price Cut, Dividend Focus, But Overhang and Weak Earnings May Hurt

By Sanghyun Park

  • Seoul Guarantee Insurance is sticking to the same playbook, focusing on boosting dividend appeal, with a better price and the 100% secondary sell-down and KDIC stake dump still in place.
  • There’s doubt about market interest, as the performance drop from 2023 to 2024 raises concerns over meeting the 200B KRW minimum dividend promise.
  • Seoul Guarantee is Korea’s only pure-play surety insurer, tied to the domestic economy. The IPO lacks a growth plan to reduce this reliance, which would’ve been a key win.

Samsung Life Insurance: Implications of Classifying Samsung Electronics as a Long-Term Holding

By Douglas Kim

  • Samsung Life Insurance (032830 KS) is considering on a special measure of classifying its stake in Samsung Electronics (005930 KS) as a long-term holding stock of up to 10 years.
  • If Samsung Life Insurance’s stake in Samsung Electronics is classified as a long-term holding, Samsung Life Insurance cannot sell Samsung Electronics stocks for at least 5 years.
  • There is an increasing probability that if Samsung Life Insurance classifies its stake in Samsung Electronics as a long-term holding, the current ownership stake structure involving Samsung Group remains intact.

Seoul Guarantee Insurance Corp IPO Preview (Significantly Lower IPO Price Range)

By Douglas Kim

  • Seoul Guarantee Insurance Corp (SGIC) is trying for another attempt at an IPO at much lower IPO price range. The IPO price range is from 26,000 won to 31,800 won.
  • At the high end of the IPO price range, the IPO offering size is 222 billion won. The IPO price range has been lowered by 34% to 39%. 
  • Despite the company’s consistent record of generating positive operating profit, its lack of sales growth and declining operating margins in 2024 remain key concerns.

Monte Dei Paschi Di Siena’s €13.3 Billion Bid for Mediobanca: First Take

By Jesus Rodriguez Aguilar

  • Proposed Deal Details: BMPS launched a €13.3B all-share offer for Mediobanca, offering a 5% premium per share. Post-merger, BMPS shareholders would own 40% of the combined entity.
  • Strategic Rationale: The merger aims to create a diversified financial powerhouse, achieving €700M in annual synergies and accelerating BMPS’s €2.9B deferred tax asset utilization for shareholder value creation.
  • Challenges and Risks: Insufficient premium, integration complexities, and shareholder dilution concerns cast doubt on deal success, alongside Mediobanca’s superior growth prospects and market positioning.

Japanese Big Cap Banks – Revisiting Interest Rate Sensitivities

By Victor Galliano

  • BoJ raised rates to 0.5% at its January policy meeting and BoJ Governor Kazuo Ueda hinted at more rate hikes; BoJ’s new Outlook Report forecasts higher core inflation in 2025
  • We reiterate our core recommendations Resona and Mizuho for their leverage to higher interest rates, their low LDRs, their high levels of cash at the BoJ and their modest valuation
  • We also keep our buys on Concordia and Shizuoka, for their leverage to higher interest rates and LDRs below 90%, along with their attractive valuations highlighted by low PEGs

Asia Real Estate Tracker (24-Jan-2025): Goldman Sachs expands into Japan with data centre JV.

By Asia Real Estate Tracker

  • Goldman Sachs’ GCI enters partnership with Asia Pacific Land in Japan for data center venture, expanding its reach in Asia.
  • CPPIB and MGRV collaborate on $350M venture in Korean rental housing, aiming to capture opportunities in the real estate market.
  • S&P forecasts rebound in China’s property market, driven by increase in secondary sales, indicating positive growth.

Geo Group Inc (GEO) – Friday, Oct 25, 2024

By Value Investors Club

  • The GEO Group is a potential investment opportunity with an asymmetric Trump trade, with a price target of $77 in a 2-year time horizon and a blue sky upside target of $103
  • The company’s market cap is $2.1 billion with an enterprise value of $3.9 billion
  • The thesis is based on the potential increase in funding for ICE monitoring under the next administration, potentially leading to the eventual spin-off of the monitoring business, resulting in GEO’s EBITDA potentially more than doubling from the current $500 million through various growth opportunities

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Energy/Materials: Greatland Gold Plc, Exxon Mobil, Natural Gas, Infinity Natural Resources, SGX Rubber Future TSR20, Venture Global LNG, SBM Offshore NV, Cemex SAB de CV and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • Which Goldies are making real cash?
  • [Earnings Preview] Exxon Q4 Profitability Faces Pressure from Lower Oil Prices and Refining Margins
  • [ETP 2025/04] WTI Falls on Trump’s Push for Higher Oil Output, Henry Hub Climbs on Colder Forecasts
  • Infinity Natural Resources (INR): Lean & Unlevered IPO Is Next Intriguing Energy Play
  • Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber
  • Venture Global Inc. (VG): First Large IPO of the Year Falls Flat Following Massive Cut in Price
  • What’s New(s) in Amsterdam – 24 January (Signify | Just Eat TakeAway.com | SBM Offshore)
  • EM Spreads – Weekly News & Views


Which Goldies are making real cash?

By Money of Mine

  • Greatland Gold is transitioning from a developer to a producer with the acquisition of Telfer and Haveron assets from Newmont.
  • In just 27 days of operation, they produced 29.9 thousand ounces of gold and 1.2 thousand tonnes of copper, exceeding expectations.
  • The company has a healthy balance sheet with 145 million in cash, no debt, and plans for mine life extensions at Telfer, including stage seven and eight cutbacks.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


[Earnings Preview] Exxon Q4 Profitability Faces Pressure from Lower Oil Prices and Refining Margins

By Suhas Reddy

  • ExxonMobil’s Q4 revenue is expected to rise 2.5% YoY while its EPS is anticipated to fall 36.3%. Annual revenue and EPS are expected to fall by 1.9% YoY and 18.1%.
  • Exxon expects Q4 2024 upstream earnings to drop USD 500–900 million QoQ due to lower crude prices, with refining margins further reducing earnings by USD 300–700 million.
  • ExxonMobil plans to invest up to USD 30 billion in low-emission projects by 2030, with its Low Carbon Solutions business expected to contribute an additional USD 2 billion in earnings.

[ETP 2025/04] WTI Falls on Trump’s Push for Higher Oil Output, Henry Hub Climbs on Colder Forecasts

By Suhas Reddy

  • For the week ending 17/Jan, U.S. crude inventories fell by 1m barrels, missing expectations of a 2.1m barrel decrease. Gasoline stockpiles rose less than expected.
  • U.S. natural gas inventories fell by 223 Bcf for the week ending 17/Jan, missing analyst expectations of a 270 Bcf drawdown. Inventories are 0.7% above the 5-year seasonal average.
  • J.P. Morgan, HSBC, TD Cowen, Barclays, and Citigroup raised their 12-month PTs on SLB post its Q4 earnings. Halliburton reported a YoY decline in Q4 revenue and EPS.

Infinity Natural Resources (INR): Lean & Unlevered IPO Is Next Intriguing Energy Play

By IPO Boutique

  • With an unlevered balance sheet, Infinity Natural Resources is set to for both organic and M&A growth post-IPO.
  • The company is coming public at a discount to peers Diversified Energy, Gulfport Energy and Magnolia Oil & Gas.
  • Early channel check of this offering revealed that the deal is oversubscribed with a high-quality schedule across different regions. 

Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber

By Vinod Nedumudy

  • Transaction valued at around US$701 million in cash proceeds
  • Goodyear to hold ground in Europe until the end of 2025
  • Goodyear joins Dutch research body TNO for crash mitigation

Venture Global Inc. (VG): First Large IPO of the Year Falls Flat Following Massive Cut in Price

By IPO Boutique

  • Venture Global priced 70 million shares at $25 and the stock closed 4% below issue in its opening session.
  • The underwriting lineup grossly mispriced the IPO from the start and needed to drastically reduce the price range of the transaction.
  • The impact to the greater IPO market will be felt on the next large transaction.

What’s New(s) in Amsterdam – 24 January (Signify | Just Eat TakeAway.com | SBM Offshore)

By The IDEA!

  • In today’s edition: • Signify | FY25 adjusted EBITA-margin guidance below expectations / to start EUR 350-450m share repurchase program / CEO Eric Rondolat to step down after the AGM 2025 • Just Eat TakeAway.com | UK delivery apps urged for tansparency on pay and hiring process • SBM Offshore | BW Offshore wins pre-FEED contract for Equinor’s Bay du Nord FPSO

EM Spreads – Weekly News & Views

By Leandro Gubler

  • The LatAm Corporate Index tightened by 3 basis points (bps) to 319 bps in the week ending on Friday, January 24, 2025.
  • U.S. Treasuries saw modest increases, with the 10-year yield up 2 bps to 4.64% and the 5-year yield also up 2 bps to 4.45%.
  • Cemex – Mexico Construction Key Indicators, YPF/Vista – Shale Boom Drives Argentina’s Energy Trade Surplus.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Tsuruha Holdings, JD.com Inc (ADR), Smithfield Foods, SGX Rubber Future TSR20, TSE Tokyo Price Index TOPIX, Noodles & Co and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table
  • [JD.com, Inc (JD US, BUY, TP US$52) TP Change]: C4Q24 Preview: Still the Safe Choice into 2025
  • Smithfield Foods (SFD): IPO Provides a Compelling Discount to Industry Peers
  • Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber
  • ETF Sale Won’t Be Concluded Soon, but as Long as BOJ Keeps Holding Them, the Problems Will Persist
  • NOODLES & CO (NDLS) – Thursday, Oct 24, 2024


Tsuruha (3391) – Welcia (3141) Future Merger Ratio – Pounding the Table

By Travis Lundy

  • In late December, a Jiji article said Tsuruha & Welcia would look to integrate by end-2025, now that they no longer need SEC approval. Odd language, but we’ll take it.
  • That means we look to what might happen between here and there. The companies will hire Legal and Financial Advisors, wait until both report FY, then start negotiating.
  • What has been the long-term trend and the trend of the last two years is different. It’s worthwhile looking at valuations and expectations to decide how to trade. It’s good.

[JD.com, Inc (JD US, BUY, TP US$52) TP Change]: C4Q24 Preview: Still the Safe Choice into 2025

By Ying Pan

  • We expect JD.com C4Q24 revenue/non-GAAP NI to be RMB337bn/9.7bn, 1.6%/6.5% above consensus, benefiting from trade-in subsidies and logistics;
  • With 2025 having four quarters of trade-in subsidy vs. 2024’s one quarter and smartphone’s participation, JD.com is on solid growth footing in our universe. 
  • We raised JD.com’s TP from US$50 to US$ 52 TP and maintain BUY rating.

Smithfield Foods (SFD): IPO Provides a Compelling Discount to Industry Peers

By IPO Boutique

  • The company is seeking a market cap of $9.1b-$10.7b based on the $23-$27 range. 
  • A high end pricing for Smithfield values the company at roughly 13.5x this year’s earnings, a sizable discount to comps Hormel Foods (about 21x) and Tyson Foods (26x).
  • It is our opinion that the business model is well-rounded, resilient and stable with multiple-organic growth levers.

Goodyear Tire To Divest Dunlop In Favor Of Sumitomo Rubber

By Vinod Nedumudy

  • Transaction valued at around US$701 million in cash proceeds
  • Goodyear to hold ground in Europe until the end of 2025
  • Goodyear joins Dutch research body TNO for crash mitigation

ETF Sale Won’t Be Concluded Soon, but as Long as BOJ Keeps Holding Them, the Problems Will Persist

By Aki Matsumoto

  • Since dividend income and unrealized gains on ETFs have significant impact on BOJ’s finances, the sales of ETF will be discussed, considering BOJ’s overall balance sheet and income/expenses as well.
  • There’re unexamined issues, whether the central bank’s purchase of stocks was really good thing, whether it distorted the secondary market, and whether management reforms were delayed by underpinning the stocks.
  • BOJ can move on to the issue of ETF disposition when the impact of policy rate hikes is recognized and the market stabilizes, but until then the problems will persist.

NOODLES & CO (NDLS) – Thursday, Oct 24, 2024

By Value Investors Club

  • Noodles & Co is currently undervalued, presenting an opportunity for turnaround
  • Despite past challenges, the restaurant chain is statistically cheap and attracting activist investors
  • With potential catalysts and a focus on value, Noodles & Co may be poised for success in the current economic landscape

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Quantitative Analysis: ASX Short Interest Weekly (Jan 17th): Xero and more

By | Daily Briefs, Quantitative Analysis

In today’s briefing:

  • ASX Short Interest Weekly (Jan 17th): Xero, Wisetech Global, Aristocrat Leisure, Macquarie


ASX Short Interest Weekly (Jan 17th): Xero, Wisetech Global, Aristocrat Leisure, Macquarie

By Ke Yan, CFA, FRM

  • We analyzed the changes in short interest of ASX Stocks as of Jan 17th (reported today) which has an aggregated short interest worth USD22.4bn.
  • We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases & decreases in short value, short as multiple of ADT.
  • We highlight short interest changes in Xero, Wisetech Global, Aristocrat Leisure, Macquarie.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Guming Holdings (Good Me) IPO: The Bear Case and more

By | Daily Briefs, ECM

In today’s briefing:

  • Guming Holdings (Good Me) IPO: The Bear Case
  • TXR Robotics IPO Preview
  • Dr Agarwal’s Healthcare Pre-IPO – Strong Revenue Growth Led by Expanding Network of Facilities
  • Sichuan Biokin (百利天恒) H-Listing: Impressive Clinical Results so Far
  • Continuum Green Energy Pre-IPO: ESG Friendly but Burning Prodigious Amounts of Cash


Guming Holdings (Good Me) IPO: The Bear Case

By Arun George

  • Guming Holdings (GUM HK) (Good me), a freshly-made tea store brand, is pre-marketing an HKEx IPO to raise US$300 million, according to press reports.
  • In Guming Holdings (Good Me) IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
  • The bear case rests on under-pressure store KPIs, unsustainable historical growth rates, declining contract liabilities, margin pressure due to competition and a sizeable pre-IPO dividend.

TXR Robotics IPO Preview

By Douglas Kim

  • TXR Robotics is getting ready to complete its IPO in KOSDAQ in March 2025. TXR Robotics is a robot and logistics automation company in Korea.
  • The company plans to offer 3.075 million shares in the IPO. The IPO price range is from 11,500 won to 13,500 won.
  • The bankers used PSR method to value TXR Robotics. The bankers used five companies including Yuil Robotics, Robotis, Neuromeka Co, Kornic Automation, and Hyundai Movex as comps.

Dr Agarwal’s Healthcare Pre-IPO – Strong Revenue Growth Led by Expanding Network of Facilities

By Akshat Shah

  • Dr Agarwal’s Health Care Ltd (8140044Z IN) is looking to raise about US$480m in its upcoming India IPO.
  • Dr Agarwal’s Health Care is a healthcare/hospital chain in India providing eyecare services, including surgeries; consultations, diagnoses, non-surgical treatments; and sells opticals, contact lens, accessories and eyecare related pharmaceutical products.
  • In this note, we talk about the company’s historical performance.

Sichuan Biokin (百利天恒) H-Listing: Impressive Clinical Results so Far

By Ke Yan, CFA, FRM

  • Sichuan Biokin is looking at a A-H listing and is looking to raise up to USD 500 million. 
  • In this note we look at the company’s fundamentals briefly including its heavyweight product BL-B01D1. We also examine its deal with BMS.
  • The stock has performed well on Shanghai STAR board since its A share listing. 

Continuum Green Energy Pre-IPO: ESG Friendly but Burning Prodigious Amounts of Cash

By Nicholas Tan

  • Continuum Green Energy Ltd (1580973D IN)  is looking to raise about US$430m in its upcoming India IPO.
  • Continuum Green Energy (CGE) is an independent power producer (IPP) with over 14 years of experience in identifying, developing, constructing and operating renewable energy projects in India.
  • In this note, we look at the firm’s past performance.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars